SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | December 15, 2023 4:30 P.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | December 15, 2023 4:30 P.M. |
Form: | S-1 | ||||||
|
Save time and jump to the most important pieces.
Gainers MicroAlgo Inc. (NASDAQ:MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. Synaptogenix, Inc. (NASDAQ:SNPX) surged 28.7% to $0.3610. Lifezone Metals Limited (NYSE:LZM) gained 27.4% to $15.29. Lifezone Metals recently reported H1 loss of $16.77 per share. SeqLL Inc. (NASDAQ:SQL) gained 26% to $18.04. Heart Test Laboratories, Inc. (NASDAQ:HSCS) climbed 25.2% to $0.4680. Cemtrex, Inc. (NASDAQ:CETX) rose 21.7% to $6.86. Cheche Group Inc. (NASDAQ:CCG) gained 21.1% to $17.99 amid continued volatility following the company's business combination with Prime Impact Acqu
Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterprise value of approximately $720 million. Existing Con
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris
SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil
SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2023.Quarter Ended June 30, 2023, Financial ResultsNet loss attributable to the Company's common stockholders for the three months ended June 30, 2023, was approximately $1,831,889, or $(0.15) per basic and diluted share, compared to a net loss of approximately $830,212, or $(0.07) per basic and diluted share for the three months ended June 30, 2022. The change in net income attributable to the Company's common stockholders was a result of: •An
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris
SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil
SAN DIEGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP))) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors (the "Board") has established a Special Committee of the Board (the "Special Committee") to explore potential strategic alternatives focusing on maximizing stockholder value. The Special Committee is comprised solely of independent directors and is charged with exploring potential strategic alternatives, including, without limitation, a business combination involving the Company, a sale of all or part of the Company's assets, joint venture arrangements and/or
S-8 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)